, the specific antigen of lipoprotein(a) (Lp[a]>, consists of structural domains (a serine protease unit, kringles 4 and 5) with marked homology to those of the corresponding domains in plasminogen. In this study, we have investigated the impact of this unique structural mimicry on the binding and activation of plasminogen by fibrin-bound tissue-type plasminogen activator at the plasma-fibrin interface. We found that the total amount of plasmin generated on the surface of fibrin was decreased in the presence of high concentrations of Lp ( 
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Lp(a) is constituted of a serine protease domain, multiple repeats of kringle 4 , and one repeat of kringle 5 of plasminogen. The number of kringle 4-encoding domains in the apo(a) gene correlates directly with apo(a) size and inversely with plasma Lp(a) concentration. 1011 Unlike plasminogen, apo(a) cannot be converted to an active protease because of a serine to arginine substitution at the position that is cleaved in plasminogen by the tissue-type plasminogen activator (t-PA). It has been reported, however, that Lp(a) may have endogenous amidolytic 12 and proteolytic 13 activity. The significance of this unique structural mimicry on the interaction of plasminogen with cell surface receptors and fibrin and its relation to the physiopathology of fibrinolysis and atherosclerosis is now under investigation in several laboratories.
14 - 17 Recent reports have shown that Lp(a) may bind to and displace plasminogen from the surface of endothelial cells and monocytes 1415 and from immobilized fibrinogen and fibrin 16 and, in addition, may inhibit plasminogen activation in purified systems. 17 In the present study, we have investigated the role of Lp(a) on the binding and the activation of plasminogen by fibrin-bound t-PA using solid-phase fibrin surfaces and whole plasma containing varying concentrations of Lp(a). Our results indicate that Lp(a) impairs the binding of plasminogen to fibrin and decreases the generation of plasmin by occupying binding sites unveiled on the fibrin surface by plasmin during ongoing plasminogen activation.
Methods

Chemicals and Reagents
All the chemicals used were of the best reagent grade commercially available. Other products were purchased from the following sources: EDTA, bovine serum albumin, and Tween 20 from Serva, Heidelberg, F.R.G.; Ultrogel AcA 44 and DEAE-Trisacryl from IBF, Villeneuve-La-Garenne, France; chromogenic substrate methylmalonylhydroxyprolylarginine-p-nitroanilide (CBS 1065) from Diagnostics Stago, Asnieres, France; lysine and gelatin-Sepharose 4B and PD-10 Sephadex G-25 M columns from Pharmacia, Uppsala, Sweden; polyvinyl chloride U-shaped microtitration plates and plate sealers from Dynatech, Marnes-La-Coquette, France; glutaraldehyde, 25% (vol/vol) aqueous solution, from TAAB Laboratories, Reading, U.K.; iodine-125-labeled Nal from Amersham, Buckinghamshire, U.K.; and nitrocellulose from OSI, Paris, France. Benzamidine and 6-aminohexanoic acid were purchased from Aldrich, Strasbourg, France. Dansyl-L-glutamyl-glycyl-L-argininechloromethyl ketone (GGACK) was obtained from France Biochem, Meudon, France; nonfat dry milk from Gloria, Courbevoie, France; and M-Partigen plates from Behringwerke, Marburg, F.R.G. Human plasmin was obtained from Boehringer Mannheim, Mannheim, F.R.G.
Buffers
Buffer A was 0.05 M NaH 2 PO 4 buffer, pH 7.4, containing 0.08 M NaCl. Buffer B was 0.05 M NaH 2 PO 4 buffer, pH 6.8, containing 0.08 M NaCl. Assay buffer was buffer A containing 0.2% (wt/vol) bovine serum albumin and 0.01% (vol/vol) Tween 20. Binding buffer was buffer B containing 0.4% (wt/vol) bovine serum albumin, 0.01% (vol/vol) Tween 20, and 2 mM EDTA. All other buffers were prepared as described in the text.
Blood Samples
Subjects consisted of healthy, normolipidemic volunteers and individuals attending the Lipid Clinic of the Endocrinology-Metabolism Service (Hopital de la Piti6, Paris) for the diagnosis and treatment of lipoprotein disorders. Patients with high levels of Lp(a) (>25 mg/dl) were detected either during a diagnostic examination or during follow-up studies for hyperlipoproteinemia. They had no antecedents of thromboembolic disease. Venous blood (^20 ml) was drawn from the forearm into sterile polypropylene tubes containing EDTA (final concentration, 1 mg/ml). Samples were immediately centrifuged at 2,000g for 15 minutes at 4°C, and plasma was removed by aspiration. Plasma samples were tested in our in vitro experimental system within 2 hours of isolation.
Eight normolipidemic donors were studied; they displayed fasting total plasma cholesterol and triglyceride levels within the normal range (140-220 and 40-110 mg/dl, respectively). Mean Lp(a) concentrations were 11.9±7.7 mg/dl (see Table 1 ) and were slightly lower than those that we reported previously for a group of 15 normolipidemic males (mean, 25±6 mg/dl, Reference 18). The normal range of Lp(a) levels can be considered to be from about 5 to 30 mg/dl. 19 
Low Density Lipoprotein and Lipoprotein(a) Purification
LDLs were isolated from normolipidemic human plasma in the density interval 1.024-1.050 g/ml by sequential preparative ultracentrifugation as described earlier. 18 Lp(a) was isolated from the plasmas of patients containing 80 mg/dl or more of Lp(a). Initially, a lipoprotein fraction enriched in Lp(a) was isolated in the density range 1.050-1.100 g/ml by sequential ultracentrifugation. Subsequently, Lp(a) was isolated by gel filtration chromatography on a BioGel A5m column (Bio-Rad, Richmond, Calif.) under the conditions of Krempler et al. 20 The central fractions of the first peak eluted from the column were taken, pooled, and concentrated by vacuum dialysis in Selectron Ultra Thimbles (Schleicher and Schull, Dassel, F.R.G.) to a protein content of about 1 mg/ml. The dialysis solution consisted of 0.01 M phosphatebuffered saline containing EDTA (0.1 mg/ml). Agarose gel electrophoresis showed Lp(a) preparations 
L. 5   10  2  78  2  10  2  98  2  10  2  170 2.3 to contain a single band of pre-)3 mobility distinguishing them from LDL ()8 mobility). The identity of the Lp(a) band on agarose gel was confirmed by its specific reactivity on immunoblots with our monoclonal antibodies to human apo(a). 21 Chemical analysis was performed by a series of enzymatic assays as described earlier. 18 Thus, the mean weight percent composition of our Lp(a) preparations was comparable to that reported elsewhere but distinct from that of LDL (Table 2 and Reference 22); note the dependence of Lp(a) chemical composition on the density interval in which it is initially isolated from plasma.
The purity of LDL was confirmed as described elsewhere. 18 Lipoprotein preparations were dialyzed against a solution containing 0.15 M NaCl, 0.01% EDTA, and 0.005% gentamicin at pH 7.4 and 4°C. The protein content of lipoprotein fractions was determined by the procedure of Lowry et al 23 with bovine serum albumin (Sigma, La Verpilliere, France) as the working standard.
Protein Purification
Glutamic acid plasminogen (Glu-plasminogen) was purified by affinity chromatography on lysineSepharose 4B, 24 ion-exchange chromatography on DEAE-Trisacryl, and gel filtration chromatography on Ultrogel AcA 44 in the presence of aprotinin. Fibrinogen was purified from fresh-frozen human plasma according to Kazal et al 25 and was depleted of plasminogen and fibronectin as described. 2426 The concentration of plasminogen and fibrinogen was determined by measuring the absorbance at 280 nm using extinction coefficienti cm =16.8 27 and 15.1, 28 respectively. Human t-PA (>95% single-chain) was the generous gift of M. Ranby (Biopool, Umea, Sweden).
Antisera and Specific Immunoglobulins
Sheep antisera against human apo(a) and human apo B-100 were prepared as described. 21 A goat antiserum against human plasminogen was obtained from Biopool. The immunoglobulin G (IgG) fractions of these antisera were separated by (NtL,) 2 SO 4 precipitation, ion-exchange chromatography on DEAE-Trisacryl, and affinity chromatography on protein A-Sepharose.
Preparation of Solid-Phase Fibrin Surfaces
The solid-phase fibrin surfaces were prepared as previously described. 29 ' 30 Briefly, polyvinyl chloride-bound stable polyglutaraldehyde derivatives were first produced by treating U-shaped microtitration polyvinyl chloride plates with 2.5% (vol/vol) glutaraldehyde in 0.1 M NaHCO 3 buffer, pH 9.5, for 2 hours at 22°C. Then, fibrinogen (0.3 /iM containing 1 mM CaCl 2 in 0.1 M NaH 2 PO 4 buffer, pH 7.4) was covalently fixed for 18 hours at 4°C. After washing, a fibrin network was generated by thrombin treatment (1 NIH unit/ml in assay buffer containing 1 mM CaCl 2 ). The excess thrombin was eluted by three washes with a high ionic strength solution (0.5 M NaCl-8 mM CaCl 2 -0.05% Tween 20) . A final wash with 5 mM NaH 2 PO 4 buffer (pH 6.8 containing 0.05% Tween 20) was performed, 
Assay Methods
The concentrations of Lp(a) in plasma and in euglobulin fractions were determined by an imniunonephelometric method as detailed earlier. 18 The assay was performed with a monospecific sheep antiserum to Lp(a) (Immuno AG, Vienna) and a reference standard containing 72.5 mg Lp(a)/dl as determined by electroimmunodiffusion (Immuno AG). This immunoassay was linear over the range of 1-500 mg/dl.
Plasminogen antigen concentration was determined by radial immunodiffusion by use of M-Partigen plates according to the instructions of the manufacturer (Behring, Rueil-Malmaison, France). Activatable plasminogen was determined in the euglobulin fraction of plasma 32 by a spectrophotometric assay consisting of fibrin-bound t-PA (see below), a volume dilution (1:80) of euglobulins in binding buffer, and 1.5 mM CBS 1065. The activation of euglobulins isolated from a pool of 20 normal plasmas was used as a reference, and the initial rate of activation under first-order conditions was determined as indicated below.
The antiplasmin activity of plasma was determined by the titration of added plasmin in a spectrophotometric assay as described previously, 33 except that residual plasmin activity was detected with 1.5 mM of the chromogenic substrate CBS 1065 at a doublewavelength absorbance ratio (A 4OS /A Ago ).
The histidine-rich glycoprotein antigen was measured by the method of Laurell 34 with a specific rabbit antiserum (Diagnostica Stago).
The activity of t-PA and its specific inhibitor (PAI-1) were measured as described previously.
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Activation of Plasma Plasminogen by Fibrin-Bound Tissue-Type Plasminogen Activator
The activation of plasminogen by t-PA on a fibrin surface was performed as indicated elsewhere. 36 Briefly, a solid-phase fibrin plate was washed three times with binding buffer, and 50 yulAvell of the same buffer containing 20 IU/ml t-PA was incubated for 1 hour at 37°C (Figure 1) . The plate was then washed twice with binding buffer to eliminate unbound proteins, and the reaction was started by adding 50 ilAvell plasma or its respective euglobulin fraction prepared as described. 32 A pair of plasmas matched for their high (>40 mg/dl) and low (<20 mg/dl) levels of Lp(a) was used for each experiment. The activation was performed in a series of three wells and was monitored for 4 hours. Every 5-15 minutes, the reaction was stopped by removing the fluid phase and washing the wells with assay buffer. When indicated, a trace amount (final concentration, 4-8 nM) of 125 I-Glu-plasminogen was added. Products present in the solid phase were analyzed by spectrophotometry, radioisotopic counting, sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) autoradiography, and specific immunoblotting as follows. Fibrin-bound plasmin activity was detected by adding 50 p,l 1.5 mM CBS 1065 in assay buffer/well and measuring the change in absorbance at a double-wavelength absorbance ratio with a microtitration plate counter (model MR 610, Dynatech) equipped with a thermostatic device to maintain temperature at a constant 37°C. Initial velocities of each reaction were calculated by using an appropriate statistical analysis of data in its original coordinate system, for example, AAws versus time, as described previously. 29 Since CBS 1065 is a plasminselective chromogenic substrate and fibrin-bound plasmin was measured at the end of the activation in the absence of plasminogen, it is very unlikely that fibrin-bound t-PA was interfering with the assay.
To quantify the amount of fibrin-bound plasminogen and to identify the molecular forms of plasmin-(ogen) bound to fibrin, the experiments were performed in the presence of 125 I-Glu-plasminogen, and the reaction was stopped with assay buffer supplemented with 1 mM benzamidine and 10 pM GGACK. At the end of the activation, the radioactivity in the wells was counted in a gamma radiation counter, and the total amount of plasminogen derivatives bound to fibrin was calculated with the following formula [plasminjfibnj,=dpm/well -r-(dpm/mol plasminogen)
The molar radioactivity (disintegrations per minute per mole protein) of plasminogen in each of the solutions (plasma or euglobulins) containing the radioactive probe was calculated from the concentration of plasminogen and the radioactivity added.
The molecular species bound to the fibrin surface were eluted by incubating 50 ^1 0.2 M 6-aminohexanoic acid for 18 hours at 22°C. The eluates were used to identify the plasminogen-derived products by SDS-PAGE and autoradiography as described previously 36 and to quantify Lp(a) as indicated below. Glu-and lysine (Lys)-plasmin used as molecular weight reference proteins were prepared from 125 IGlu-plasminogen as described. 37 
Quantification of Fibrin-Bound Lipoprotein(a) by Dot Immunobinding
Lp(a) present in the eluates from fibrin was assayed by quantitative dot blotting as follows ( Figure  1 ). Amounts of 2 /il of each eluate or of a series of purified Lp(a) dilutions used as a standard were adsorbed on a nitrocellulose membrane previously The efficiency of the elution (ratio of eluted products to total bound products) was calculated by probing the fibrin surface with the sheep radiolabeled antibody against apc(a) before and after the elution procedure.
Radioiodination of Proteins
Glu-plasminogen and the purified IgG against apo(a) were radioiodinated with 
Results
Characteristics of Plasmas
A total of 20 different plasmas were studied. The levels of Lp(a), plasminogen, a 2 -antiplasmin, and histidine-rich glycoprotein are indicated in Table 1 . All plasmas had normal levels of the fibrinolytic components, including t-PA and PAI-1 activities (not shown) but differed in their concentration of Lp(a) antigen. Plasminogen was more than 95% activatable as compared with a pool of normal plasma and assessed in a system where the plasminogen-binding proteins, a 2 -antiplasmin and the histidine-rich glycoprotein, were eliminated, and the possible effect of Lp(a) was minimized by testing the euglobulin fraction of plasma at a high dilution. Under these conditions, the concentration of plasminogen was the rate-limiting factor.
Activation of Plasminogen by Fibrin-Bound Tissue-Type Plasminogen Activator
The formation of fibrin by thrombin-catalyzed fibrinopeptide cleavage from solid-phase fibrinogen was verified by the disappearance of immunoreactivity of the monoclonal antibody Y18-HRP with solidphase fibrinogen after treatment with thrombin. Under the conditions described, the maximal fibrin surface density that could be obtained was 410±4 fmol/cm 2 . 30 The characteristics of the solid-phase fibrin support, which constitutes a useful model for plasminogen activation experiments, have been previously described. 30 The intra-assay and interassay coefficients of variations derived from measurements of plasmin activity were 2.5 and 8.1, respectively. Care was taken to perform the activation experiments with a minimum of delay from sampling (<2 hours); during this period, plasmas were kept at 4 C. The plasmas were supplemented with a constant amount (final concentration, 4-8 nM) of 125 I-Gluplasminogen, and the activation was performed as indicated ( Figure 1 ). As previously shown in this system, 36 the activation of human plasma plasminogen by fibrin-bound t-PA as a function of time results in the generation of active Glu-plasmin (Figure 2 Accordingly, in the present study all plasminogenderived products generated from the different plasmas at each time point of the activation were identified as Glu-plasmin. Such Glu-plasmin was active against the chromogenic substrate CBS 1065. Figure  2 represents the results obtained with a representative control plasma. The amount of plasmin generated at each time point was quantified by transforming the radioactivity in the wells into mass of protein as indicated in "Methods." The results obtained with a representative pair of plasmas matched for their extremely low and high contents of Lp(a) are shown in Figure 3 , upper panel. The amount of plasmin bound to fibrin increased progressively as a function of time throughout the activation period. The activation of plasminogen in the euglobulins was enhanced due to the absence of a 2 -antiplasmin and histidine-rich glycoprotein, the two plasminogen-binding glycoproteins present in plasma. However, the initial rate of generation of plasmin at the fibrin surface (Figure 3, upper panel) was considerably delayed in both the plasma (1.9 versus 3.3 fmol/min) and the corresponding euglobulin fraction (7.3 versus 10.1 fmol/min) containing 110 mg Lp(a)/ dl. At 10 mg Lp(a)/dl, the total amount of plasmin bound per well at 4 hours was 230 fmol in plasma and 630 fmol in the euglobulins. In contrast, these values were reduced by 42% and 23%, respectively, in the Lp(a)-rich plasma.
To further investigate the effect of Lp(a) on the binding and activation of plasminogen, the Lp(a)-poor plasma was supplemented with the equivalent of 100 mg/dl of either purified Lp(a) or LDL, and activation experiments were performed with whole plasma or the euglobulin fraction. The results (Figure 3 , lower panel) were similar to those obtained with the plasmas containing native Lp(a) (Figure 3 , upper panel). The amount of plasmin bound to fibrin at 4 hours was decreased by a factor of 36% (250 fmol) when activation was performed in the euglobulin fraction containing Lp(a) (485 fmol), as compared with the activation in the presence of the euglobulins containing LDL (735 fmol). The values obtained with plasma showed a decrease of 29%: 180 fmol in the presence of Lp(a) and 255 fmol in the presence of LDL.
Activation experiments were performed with all the plasmas shown in Table 1 . The results are grouped in Figure 4 and are expressed as the percentage of plasmin generated by each individual plasma with a high level of Lp(a) as compared with the corresponding value obtained with the paired control plasma. Differences were considered significant at the p< 0.05 level and were calculated by the Wilcoxon test. A decrease in the amount of plasmin bound to the wells as a function of Lp(a) concentration was observed in the plasmas and the euglobulin suspensions, as indicated by the negative slope of the linear regression analysis of data. The amount of plasmin bound to the fibrin surface in the presence of less than 20 mg/dl Lp(a) was 287±112 fmol for the plasmas and 754 ±310 fmol for the euglobulins, while the corresponding amount in samples with Lp(a) levels greater than 60 mg/dl were 197±65 (/?<0.05) and 554±169 fmol (/?<0.05), respectively. It is im- portant to note that two of the plasmas tested (those of H.R. and P.I. in Table 1 ) failed to show a decrease in the amount of plasmin generated at the fibrin surface despite high levels of Lp(a).
Identification of Glu-Plasmin and Quantification of Lipoprotein(a) at the Surface of Fibrin
The products eluted from the surface of fibrin with 6-aminohexanoic acid were identified as Glu-plasmin by SDS-PAGE autoradiography ( Figure 2 ) and as Lp(a) by dot immunobinding by use of specific radiolabeled antibodies. The amount of Lp(a) was quantified by reference to an Lp(a) standard curve run under the same conditions ( Figure 5 ). The amount of fibrin-bound Lp(a) at 4 hours' activation with the euglobulins of plasma from subject G.U. represented in Figure 3 , upper panel, was 40 fmol/well (M r -5x10*). The amount of plasmin bound to the same surface was decreased by 250 fmol.
Discussion
The recent demonstration of marked homologies between structural domains of plasminogen and apo(a) suggests that a common exon or exon cluster might have been shuffled into these genes to incorporate a common function into the expressed proteins. The existence of such a common function and its consequence -the binding of Lp(a) to fibrin and impairment of the binding and activation of plasminogen by fibrin-bound t-PA-is clearly demonstrated by our data. We have used a sensitive, solid-phase heterogeneous system, which allows the study of plasminogen activation at the plasma-fibrin interface and makes feasible the analysis of products bound to the solid phase. 30 In this study, t-PA was first bound to intact fibrin, a condition that may be equivalent to the binding of t-PA to the surface of a clot, and the subsequent appearance of plasminogen derivatives was determined as the fibrin was degraded. As previously shown, 36 plasminogen was continuously bound to the fibrin surface as indicated by its transformation to active Glu-plasmin. Both the initial rate of plasmin generation and the total amount of plasmin generated at the fibrin surface was about 30% lower when plasma was used instead of the euglobulin fractions (Figure 3 ). This finding is most probably related to the competitive effect of both a 2 -antiplasmin 36 and histidine-rich glycoprotein (D. Rouy and E. AnglesCano, unpublished observations), two plasminogenbinding a-globulins separated from plasma by euglobulin precipitation. The initial rate and the total amount of plasmin generated on the fibrin surface were further decreased in plasmas containing a high concentration of Lp(a) and in the corresponding euglobulin fractions: 287±112 versus 197+65 fmol for plasma and 754±310 versus 554±169 fmol for the euglobulins. When the amount of plasmin generated in samples with a high level of Lp(a) was expressed as a percentage relative to the amount of plasmin generated by their paired matched controls containing low levels of Lp(a), an inverse relation between the level of Lp(a) and the amount of plasmin generated at the surface of fibrin was found (Figure 4) . The difference between both groups of samples was significant at p<0.05 for both the plasmas and the euglobulins. Since the a-globulins were absent from the euglobulins and more than 95% of the Lp(a), a /3-globulin, was coprecipitated with the euglobulins, it was tempting to ascribe this effect to the presence of Lp(a). This hypothesis was further confirmed in parallel experiments in which a plasma with an extremely low content of Lp(a) was supplemented with purified Lp(a) to a final concentration equivalent to 100 mg/dl; LDL, a particle similar to Lp(a) but lacking apo(a), served as a control. In the presence of Lp(a), the amount of active plasmin generated at the fibrin surface was lower than in the presence of LDL (Figure 3 ). This finding indicated clearly that Lp(a) was interfering with the binding and the activation of plasminogen at the fibrin surface. Due to the structural homologies between the kringle 4 domain of plasminogen and similar structures present in the apo(a) glycoprotein of Lp(a), the possible competition between Lp(a) and plasminogen for binding to fibrin as a mechanism to explain the observed decrease in plasmin generation was investigated. It was found that Lp(a) was indeed bound to fibrin. Moreover, in a recent report, we 39 have shown that binding is related to the proteolysis of fibrin by plasmin. In the representative experiment shown in Figure 3 , the total amount of Lp(a) detected at the end of the experiment was 40 fmol, while the amount of plasmin bound was decreased by 250 fmol. The difference in molecular mass between plasminogen and Lp(a) might impair, by steric hin-drance, the one to one stoichiometry of substitution at the surface of fibrin. The binding was related to the unveiling of new C-terminal Lys residues by plasmin as indicated by 1) the ability of 6-aminohexanoic acid to elute fibrin-bound Lp(a) and plasmin and 2) the disappearance of the binding after treatment of the degraded surface with carboxypeptidase B. 39 This observation is in agreement with a recent report 16 that plasmin catalyzes binding of Lp(a) to immobilized fibrin in a static system based on the original solid-phase fibrin model described by us. 30 In addition, it has been shown in purified systems that Lp(a) inhibits the activation of plasminogen by t-PA in the presence of fibrinogen fragments. 17 The present study offers the advantage of studying these interactions in a dynamic kinetic model that follows the known biochemistry of fibrinolysis under conditions that are as close as possible to the physiological model: the plasma-fibrin interface and activation of plasminogen by fibrin-bound t-PA.
From these observations, we can conclude that the kringle domains of apo(a) may play an important inhibitory role in fibrinolysis. Similar functional analogies in the binding of Lp(a) to cellular receptors for plasminogen or to proteins with affinity for plasminogen have been recently demonstrated.
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The accumulation of Lp(a) instead of plasminogen at the surface of fibrin might interfere not only with the lysis of clots due to the inability of apo(a) to be activated to a serine protease, but may also favor the accumulation of cholesterol in thrombi of the vessel wall. Indeed, decreased fibrinolysis with accumulation of Lp(a) at sites of vascular injury may represent the link between elevated Lp(a) levels and development of atherosclerosis.
The size heterogeneity of the apo(a) subunit and the correlation between apo(a) size and Lp(a) concentration render complex the analysis of its interactions with plasminogen. The absence of an effect of Lp(a) in two of the plasmas tested may be related to this phenomenon. Further studies are therefore necessary to characterize the functional consequences of this heterogeneity and to quantitatively determine the parameters of the interaction of Lp(a) with fibrin. D Rouy, P Grailhe, F Nigon, J Chapman and E Anglés-Cano
